Lexaria Bioscience (LEXX) Capital Expenditures (2010 - 2026)
Lexaria Bioscience (LEXX) posted Capital Expenditures of $40816.0 for Q1 2026, up 4081500.0% sequentially from $1.0 in Q3 2025, and up 4081500.0% YoY from N/an in Q1 2025.
Lexaria Bioscience (LEXX) Capital Expenditures (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Capital Expenditures for 15 years, with the latest figure at $40816.0 in Q1 2026.
- Quarterly Capital Expenditures rose 4081500.0% year-over-year to $40816.0 in Q1 2026, while the trailing twelve-month figure through May 2026 was $40817.0 (down 39.67% YoY) and the FY2025 annual result came in at $24646.0, down 42.7% from the prior year.
- Capital Expenditures rose to $40816.0 in Q1 2026 per LEXX's latest filing, from $1.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $43014.0 in Q3 2024 and troughed at -$1.0 in Q2 2025.
- A 5-year average of $14904.1 and a median of $10030.5 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures plunged 100.0% in 2025, then surged 4081500.0% in 2026.
- Over 5 years, Capital Expenditures stood at $20500.0 in 2022, then tumbled by 35.38% to $13248.0 in 2023, then soared by 86.03% to $24645.0 in 2024, then tumbled by 100.0% to $1.0 in 2025, then soared by 4081500.0% to $40816.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $40816.0, $1.0, and -$1.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 40,816.00 |
| Feb 28, 2026 | 40,816.00 |
| Aug 31, 2025 | 1.00 |
| Aug 31, 2025 | 1.00 |
| May 31, 2025 | -1.00 |
| May 31, 2025 | -1.00 |
| Feb 28, 2025 | 1.00 |
| Feb 28, 2025 | 1.00 |
| Nov 30, 2024 | 24,645.00 |
| Nov 30, 2024 | 24,645.00 |
| Aug 31, 2024 | 43,014.00 |
| Aug 31, 2024 | 43,014.00 |
| Feb 28, 2023 | 13,248.00 |
| Feb 28, 2023 | 13,248.00 |
| Nov 30, 2022 | 20,500.00 |
| Nov 30, 2022 | 20,500.00 |
| Aug 31, 2022 | 4.00 |
| Aug 31, 2022 | 4.00 |
| May 31, 2022 | 6,813.00 |
| May 31, 2022 | 6,813.00 |